title: The safety and usefulness of high-dose-rate endoluminal brachytherapy as a boost in the treatment of patients with esophageal cancer with external beam radiation with or without chemotherapy.
abstract: OBJECTIVE
  This study reports the results of a single-institution experience with high-dose-rate brachytherapy (HDRBT) used as a boost in the treatment of esophageal cancer with external beam radiation therapy (ERT) with or without chemotherapy.
  
  
  METHODS
  Patients without evidence of metastatic disease were identified. HDRBT was given before ERT with a dose of 20 Gy in 5 fractions. Patients with a Karnofsky performance of more than 70 received treatment with 50 Gy in 25 fractions and concurrent 5-fluorouracil and cis-platinum during Weeks 1 and 5, whereas patients with a Karnofsky performance of less than 70 were treated with radiation therapy alone with 35 Gy in 14 fractions.
  
  
  RESULTS
  Fifty-three patients received HDRBT treatment with combined ERT and chemotherapy and 17 patients with ERT alone. The incidence of acute bone marrow toxicity was 55% Grade 2 and 15% Grade 3, and 85% of patients had Grade 2 esophagitis. With a median follow-up time of 26 months, the median survival was 21 months; the 2-year local recurrence was 25%, and the 5-year survival rate was 28%.
  
  
  CONCLUSIONS
  HDRBT is safe and beneficial for local control in the radical treatment of patients with esophageal cancer.
authors.affiliation: Department of Radiation Oncology, McGill University Health Center, Montréal, Québec, Canada. te.vuong@muhc.mcgill.ca
authors.forename: Té
authors.initials: T
authors.lastname: Vuong
authors.forename: Peter
authors.initials: P
authors.lastname: Szego
authors.forename: Marc
authors.initials: M
authors.lastname: David
authors.forename: Michael
authors.initials: M
authors.lastname: Evans
authors.forename: Josée
authors.initials: J
authors.lastname: Parent
authors.forename: Serge
authors.initials: S
authors.lastname: Mayrand
authors.forename: Robert
authors.initials: R
authors.lastname: Corns
authors.forename: Pascal
authors.initials: P
authors.lastname: Burtin
authors.forename: Sergio
authors.initials: S
authors.lastname: Faria
authors.forename: Slobodan
authors.initials: S
authors.lastname: Devic
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000532:radiotherapy; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001918:Brachytherapy / Q000009:adverse effects / Q000379:methods*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000532:radiotherapy; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D004938:Esophageal Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D004941:Esophagitis / Q000209:etiology; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008875:Middle Aged; D011879:Radiotherapy Dosage; D016019:Survival Analysis
chemical_list: D002945:Cisplatin; D005472:Fluorouracil